Destiny Pharma teams up with US Department of Veterans Affairs to find 'new attributes' for next-generation medicine
NTCD-M3 is being developed to combat Clostridioides difficile infections (CDI) in the gut
Company
Destiny Pharma PLC
LON:DEST
Destiny Pharma PLC is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.
97 stories · page 4 of 5
Destiny Pharma to present clinical study data at infectious diseases congress
The presentation is entitled, "Repeated doses of exeporfinium chloride (XF-73) nasal gel over 24 hours significantly reduced the burden of Staphylococcus aureus nasal carriage in at-risk surgical patients"
Destiny Pharma hails G7 health ministers for highlighting "silent pandemic" of antimicrobial resistance
“We are very pleased that the G7 Health Ministers Meeting has again strongly supported investment, regulatory and commercial incentives for drug developers,” said the company's chief executive, Neil Clark
Destiny Pharma makes significant strides toward phase III evaluation of potential breakthrough C.diff treatment
CEO Neil Clark said: "We have made significant progress since closing the £10.4mln equity funding in December 2020 that enabled the NTCD-M3 acquisition.”
Archive
FTSE 100 closes in the red, Wall Street fares no better
On the plus side, we've got this far without rehashing the old Star Wars "May the fourth" joke ... d'oh!
Destiny Pharma sits on cash pile as it focuses on two lead assets
The firm said it has “a great opportunity” as a UK biotechnology company focused on infection prevention
Destiny Pharma says anti-infection gel trial results 'exceptionally high'
The candidate achieved a 99.5% reduction in S. aureus bacterial nasal carriage, which the company said is a very effective reduction by accepted clinical measures
Destiny Pharma receives support from US government to develop ground-breaking wound infection treatment
The drug developer is teaming up with the National Institute of Allergy and Infectious Diseases
Destiny Pharma chief scientific officer to join COVID taskforce
Dr Bill Love will advise on the ‘delivery’ of research and innovation funding
Destiny Pharma lands Brazilian patent for post-surgical nasal gel; expects to share phase IIb results at the end of next month
The Brazilian authorities have issued what is known as a notice of allowance pending full approval next month
Destiny Pharma appoints C. difficile expert to its scientific advisory board
Professor Mark Wilcox is Head of R&D in Microbiology at the Leeds Teaching Hospitals
Destiny Pharma has announced the appointment of Dr Stephanie Bewick as its chief business officer
Most recently, Bewick was vice president, Business Development at Summit Therapeutics, a NASDAQ-listed infectious disease company, leading the out-licensing and in-licensing activities, pipeline positioning and technology valuation
Destiny Pharma completes enrolment for XF-73 trial on schedule
XF-73 has been awarded both qualifying infectious disease product and Fast Track status by the US Food and Drug Administration
Destiny Pharma starts preparations for its phase III trial of C. difficile drug; makes key appointment
The group has also brought on board high-level expertise in the form of Professor Dale Gerding, who has joined the drug developer’s scientific advisory board as well as becoming a “key consultant”
Destiny Pharma inks collaboration agreement with SporeGen for COVID-19 preventive nasal spray
The pair received an £800,000 grant from Innovate UK to fund the majority of the £1mln preclinical programme
Archive
Dechra Pharma at the giddy-up after solid start to the new fiscal year
A look at some of the major movers in London on Monday
Investments and investor services
FTSE 100 closes in the red as Brexit and trade war fears continue to hit sentiments
The International Monetary Fund issued a warning, saying a "no-deal" Brexit would send the British economy into severe shock
Archive
Sumo no heavyweight but finals should show good development, yet unlikely to divert from Brexit
The Day Ahead will continue to be dominated by the Brexit saga, with the corporate news diary limited to small cap firms, including City Pubs Group, Destiny Pharma
Archive
Retailers Tesco and ASOS to provide the main corporate excitement in coming week
Also on the retail front, WH Smith and Dunelm will issue updates as well in the Week Ahead, while on the macro front an ECB rate decision and US FOMC meeting minutes are also due